A Safety and Efficacy Study of T0903131 (INT131) Besylate to Treat Type 2 Diabetes Mellitus

NCT00952445 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

70

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes Mellitus, Type II

Interventions

DRUG: T0903131 Besylate
DRUG: Placebo

Sponsor

InteKrin Therapeutics, Inc.